Skip to main content

Table 1 Baseline data

From: Impact of Ivabradine on renal function in septic patient with early renal impairment

 

Group C

(n=25)

Group I

(n=25)

Tests

t/X2

P-value

Age (years)

44.16±10.54

45.32±9.78

0.404

0.688

Weight (kg)

83.60±8.23

85.32±9.42

0.688

0.495

Cause of Sepsis

 Pneumonia

12(48%)

13(52%)

0.267

0.966

 Abdominal

8(32%)

7(28%)

 Necrotizing fasciitis

2(8%)

3(12%)

Septic wound

2(12%)

2(8%)

Amount of fluid prior to inclusion

5410.48±490.81

5394.00±398.98

0.130

0.897

SOFA score (Median (IQR)

9 (7 -12.25)

8(6.75-12)

 

0.496

Optimization of adequate resuscitation

 Serum lactate

1.96±0.46

2.15±0.44

1.542

0.130

 MAB

68.20±1.29

67.56±1.66

1.522

0.135

 CVP

9.72±1.28

10.24±1.16

1.505

0.139

 (SvO2)

69.40±3.32

70.16±3.20

0.825

0.414

HERAT RATE

98.20±7.21

96.84±3.33

0.856

0.396

 Serum Cystatin C (mg/l)

1.71±0.16

1.79±0.17

1.571

0.123

eGFR C (ml/min/1.73 m2)

44.28±2.88

45.76±3.24

1.706

0.094

DAILY URINE OUTPUT

844.52±107.76

838.00±118.52

0.204

0.840

DAILY NOREPIEPHRINE : 0.3-0.5 μg/Kg/Min

0.44±0.16

0.47±0.20

0.539

0.592

  1. Group (C): received conventional treatment sepsis and placebo tablet, group (I): received conventional treatment sepsis and Ivardrabine tablet, (SvO2): mixed venous saturation, CVP: central venous pressure, MAP: mean arterial blood pressure, eGFR C :estimated glomerular filtration rate based on cystatin C